The Allergan BIOCELL Implants — Textured Shells Tied to Cancer and 33 Deaths

When Allergan announced a voluntary worldwide recall of its BIOCELL textured breast implants and tissue expanders on July 24, 2019 — at the request of the U.S. Food and Drug Administration — the gap between the product’s marketing and its documented harm was already a measurable oncologic toll: the FDA cited 573 unique cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) worldwide, of which 481 were attributable to Allergan devices, and 33 patient deaths, with 12 of the 13 deaths for which the implant maker was known confirmed to involve an Allergan implant. The agency’s analysis put the BIA-ALCL risk of BIOCELL macrotextured shells at roughly six times that of textured implants from other manufacturers then on the U.S. market. The implant had been sold as an ordinary reconstructive and cosmetic option; what it delivered, in a small but non-trivial fraction of recipients, was a lymphoma growing in the scar capsule around the device.

The harm was not a manufacturing defect in the conventional sense — it was the shell’s defining feature. BIOCELL was a macrotextured surface produced by a “salt-loss” process that pressed salt crystals into the silicone and dissolved them away, leaving a deeply pitted, high-surface-area shell originally marketed to anchor the implant and reduce capsular contracture. That same surface area is now the leading mechanistic suspect: it harbored more bacteria, sustained chronic biofilm and immune stimulation against the textured surface, and over years of low-grade inflammation appears to have driven T-cell transformation into ALCL in the periprosthetic capsule. The disease typically presented as a delayed seroma or mass years after implantation; caught early and treated by complete capsulectomy it was often curable, but advanced cases were lethal.

Regulators abroad moved first. France’s medicines agency, the ANSM, declined to renew the CE mark for Allergan’s macrotextured implants in December 2018 and in April 2019 became the first national regulator to ban macrotextured and polyurethane breast implants outright as a precaution. The FDA, which had publicly flagged a possible breast-implant/ALCL association as early as January 2011, did not force Allergan’s hand until July 2019 — by which point hundreds of thousands of the shells were already in patients’ bodies and would remain there, since neither the FDA nor Allergan recommended removing implants from asymptomatic women. As cumulative reporting matured, the case count climbed: by 2023 the FDA had documented on the order of 1,264 BIA-ALCL cases globally and 63 deaths, with roughly 85 percent of cases tied to Allergan textured devices. The BIOCELL recall became the modern textbook case of a device hazard that was rare, latent, and surface-intrinsic — and of a regulatory system that recognized the signal years before it acted on it.